Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
Completed
Worldwide Clinical Trials
Phase 3
2013-06-01
The purpose of the study was to assess the efficacy of induction treatment with
buprenorphine/naloxone (BNX) sublingual tablet s compared with induction treatment with
buprenorphine only. The hypothesis is that starting directly on OX219 works equally well
(e.g. not significantly worse) as starting on buprenorphine only and switching to OX219 on
Day 3.
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
Completed
Orexo AB
Phase 3
2013-06-01
The purpose of the study was to assess the efficacy of induction treatment with
buprenorphine/naloxone (BNX) sublingual tablet s compared with induction treatment with
buprenorphine only. The hypothesis is that starting directly on OX219 works equally well
(e.g. not significantly worse) as starting on buprenorphine only and switching to OX219 on
Day 3.
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
Completed
Worldwide Clinical Trials
Phase 4
2013-07-01
The purpose of this study was to assess safety, efficacy, and treatment retention following
extended treatment with OX219, a higher-bioavailability buprenorphine/naloxone (BNX)
sublingual tablet formulation in opioid-dependent patients who completed 1 of 2 primary
efficacy and safety studies of OX219.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
